News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,426 Results
Type
Article (41492)
Company Profile (266)
Press Release (665668)
Multimedia
Podcasts (57)
Webinars (12)
Section
Business (206084)
Career Advice (2029)
Deals (35719)
Drug Delivery (101)
Drug Development (81538)
Employer Resources (173)
FDA (16308)
Job Trends (15137)
News (348176)
Policy (32887)
Tag
Academia (2602)
Accelerated approval (6)
Adcomms (22)
Allergies (89)
Alliances (49937)
ALS (96)
Alzheimer's disease (1433)
Antibody-drug conjugate (ADC) (133)
Approvals (16300)
Artificial intelligence (264)
Autoimmune disease (22)
Automation (17)
Bankruptcy (366)
Best Places to Work (11782)
BIOSECURE Act (19)
Biosimilars (109)
Biotechnology (186)
Bladder cancer (79)
Brain cancer (28)
Breast cancer (290)
Cancer (2325)
Cardiovascular disease (179)
Career advice (1696)
Career pathing (30)
CAR-T (157)
Cell therapy (439)
Cervical cancer (20)
Clinical research (66395)
Collaboration (861)
Company closure (2)
Compensation (565)
Complete response letters (19)
COVID-19 (2620)
CRISPR (41)
C-suite (252)
Cystic fibrosis (102)
Data (2326)
Decentralized trials (2)
Denatured (19)
Depression (48)
Diabetes (277)
Diagnostics (6451)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (106)
Drug shortages (28)
Duchenne muscular dystrophy (99)
Earnings (87365)
Editorial (39)
Employer branding (22)
Employer resources (147)
Events (113682)
Executive appointments (743)
FDA (17688)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (769)
Gene editing (110)
Generative AI (20)
Gene therapy (318)
GLP-1 (732)
Government (4483)
Grass and pollen (4)
Guidances (158)
Healthcare (19078)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (130)
Indications (29)
Infectious disease (2766)
Inflammatory bowel disease (146)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (98)
Interviews (315)
IPO (16612)
IRA (40)
Job creations (3769)
Job search strategy (1440)
Kidney cancer (10)
Labor market (43)
Layoffs (484)
Leadership (17)
Legal (8015)
Liver cancer (76)
Lung cancer (327)
Lymphoma (158)
Machine learning (9)
Management (58)
Manufacturing (330)
MASH (77)
Medical device (13505)
Medtech (13510)
Mergers & acquisitions (19675)
Metabolic disorders (713)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (100)
Neuropsychiatric disorders (30)
Neuroscience (2002)
NextGen: Class of 2025 (6632)
Non-profit (4553)
Now hiring (40)
Obesity (377)
Opinion (215)
Ovarian cancer (81)
Pain (92)
Pancreatic cancer (88)
Parkinson's disease (153)
Partnered (22)
Patents (245)
Patient recruitment (115)
Peanut (49)
People (58045)
Pharmaceutical (70)
Pharmacy benefit managers (19)
Phase I (20665)
Phase II (29237)
Phase III (21815)
Pipeline (1369)
Policy (149)
Postmarket research (2588)
Preclinical (8815)
Press Release (64)
Prostate cancer (109)
Psychedelics (32)
Radiopharmaceuticals (250)
Rare diseases (389)
Real estate (6110)
Recruiting (66)
Regulatory (22533)
Reports (47)
Research institute (2362)
Resumes & cover letters (351)
Rett syndrome (6)
RNA editing (5)
RSV (43)
Schizophrenia (73)
Series A (133)
Series B (88)
Service/supplier (11)
Sickle cell disease (52)
Special edition (19)
Spinal muscular atrophy (155)
Sponsored (29)
Startups (3647)
State (2)
Stomach cancer (13)
Supply chain (70)
Tariffs (50)
The Weekly (36)
Vaccines (706)
Venture capitalists (42)
Weight loss (241)
Women's health (36)
Worklife (16)
Date
Today (185)
Last 7 days (966)
Last 30 days (3133)
Last 365 days (32696)
2025 (11922)
2024 (35410)
2023 (40314)
2022 (51468)
2021 (56048)
2020 (54519)
2019 (47101)
2018 (35483)
2017 (32513)
2016 (31883)
2015 (37909)
2014 (31640)
2013 (26708)
2012 (28968)
2011 (29628)
2010 (27717)
Location
Africa (750)
Alabama (54)
Alaska (7)
Arizona (238)
Arkansas (13)
Asia (38275)
Australia (6271)
California (6421)
Canada (2072)
China (539)
Colorado (274)
Connecticut (282)
Delaware (158)
Europe (82934)
Florida (957)
Georgia (216)
Idaho (60)
Illinois (563)
India (25)
Indiana (324)
Iowa (11)
Japan (172)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (926)
Massachusetts (4785)
Michigan (226)
Minnesota (405)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1795)
New Mexico (28)
New York (1810)
North Carolina (1030)
North Dakota (9)
Northern California (2830)
Ohio (210)
Oklahoma (14)
Oregon (36)
Pennsylvania (1427)
Puerto Rico (13)
Rhode Island (33)
South America (1131)
South Carolina (26)
South Dakota (1)
Southern California (2410)
Tennessee (106)
Texas (956)
United States (24136)
Utah (189)
Virginia (151)
Washington D.C. (65)
Washington State (569)
West Virginia (3)
Wisconsin (58)
707,426 Results for "biogen idec inc north carolina".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Tariffs Keep Biogen Execs Busy in Q1 but Impacts Expected To Be Minimal
Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he does not expect major impacts—at least for 2025.
May 1, 2025
·
3 min read
·
Annalee Armstrong
Bio NC
Leading Academic Medical Center Becomes First in North Carolina to Offer Sedation-Free TNE With the EvoEndo® Endoscopy System
EvoEndo®, Inc. announces that Duke Health is the first provider in the region to bring Sedation-Free TNE of the Upper Gastrointestinal Tract using the EvoEndo® Single-Use Endoscopy System to patients in North Carolina.
June 28, 2024
·
3 min read
Mergers & acquisitions
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
January 27, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
December 24, 2024
·
2 min read
Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina
Immunovia announces that the company will move its lab and U.S. headquarters to Research Triangle Park in North Carolina in May 2024.
April 29, 2024
·
2 min read
Press Releases
AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA
December 6, 2024
·
8 min read
Legal
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
January 21, 2025
·
2 min read
·
Tristan Manalac
Job Trends
Fujifilm Pumps $1.2B into CDMO Capacity in North Carolina, Eyes 680 New Jobs by 2031
The global contract development and manufacturing organization is investing $1.2 billion to boost production capabilities at its Holly Springs, North Carolina, site including mammalian cell culture bioreactors.
April 12, 2024
·
2 min read
·
Tristan Manalac
Manufacturing
Amgen to Add 370 New Jobs in North Carolina With $1B Manufacturing Investment
It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity as it prepares to enter the obesity space with MariTide.
December 6, 2024
·
2 min read
·
Tristan Manalac
Neuroscience
Biogen Submits Offer to Buy Embattled Partner Sage
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.
January 13, 2025
·
3 min read
·
Heather McKenzie
1 of 70,743
Next
